• BCL-2 Targeting Validated in Heterogeneous CRPC via Single-C

  2026-06-12

  This study integrates advanced single-cell imaging and therapeutic modeling to establish BCL-2 as a therapeutic target across diverse castration-resistant prostate cancer (CRPC) subtypes. Findings show that AR pathway inhibition induces BCL-2 expression, and clinical trial results support combined targeting of AR and BCL-2 in overcoming therapy resistance.

• Protease Inhibitor Cocktail: Safeguarding Protein Integrity

  2026-06-12

  The Protease Inhibitor Cocktail (100X in DMSO, EDTA plus) empowers researchers to preserve labile proteins throughout demanding workflows, from Western blotting to co-immunoprecipitation. By integrating broad-spectrum inhibition with optimized protocols, this solution—trusted by APExBIO—enables reproducible results even in advanced translational oncology studies targeting nucleic acid metabolism.

• Verapamil HCl: Advancing Translational Research in Apoptosis

  2026-06-11

  This thought-leadership article explores the strategic deployment of Verapamil HCl in translational research, focusing on its mechanistic role as an L-type calcium channel blocker. Blending biological rationale, experimental evidence, and practical guidance, the article highlights innovative approaches for leveraging Verapamil HCl in apoptosis induction and inflammation attenuation, with consideration of multidrug resistance mechanisms. Integrating recent literature and competitive benchmarking, the discussion underscores APExBIO’s product reliability while charting new territory in workflow optimization for myeloma and arthritis models.

• Bradykinin: Endothelium-Dependent Vasodilator in Workflow De

  2026-06-11

  Bradykinin, a potent endothelium-dependent vasodilator, empowers precision research in vascular, inflammation, and pain signaling studies. Discover how APExBIO's high-purity Bradykinin facilitates robust experimental workflows, advanced use-cases, and reproducible data for cardiovascular and inflammation research.

• CX-5461: RNA Polymerase I Inhibitor Workflows in Cancer Rese

  2026-06-10

  CX-5461, a potent RNA polymerase I inhibitor from APExBIO, enables selective disruption of rRNA synthesis to induce robust autophagy and senescence in cancer models. This article details optimized protocols, application strategies, and troubleshooting tips for using CX-5461 in advanced solid tumor research, anchored by the latest findings in cervical cancer.

• FPH1 (BRD-6125) and Optogenetic Control: Elevating Hepatocyt

  2026-06-10

  This thought-leadership article explores how FPH1 (BRD-6125), a small molecule hepatocyte proliferation enhancer, is accelerating functional primary human hepatocyte expansion and enabling advanced workflows for translational research. Mechanistic insights are paired with actionable strategies, protocol guidance, and a forward-looking synthesis integrating optogenetic gene control, drawing on cutting-edge evidence—including regulated gene therapy with light-inducible RNA-releasing proteins—for unprecedented precision in liver cell engineering.

• Degarelix Acetate: Rapid GnRH Antagonism in Prostate Cancer

  2026-06-09

  This article reviews the pivotal findings of Klotz (2009) on Degarelix acetate, a third-generation GnRH receptor antagonist that enables rapid, sustained testosterone suppression without the flare seen with agonists. The study’s clinical and mechanistic insights have shaped current prostate cancer research and therapeutic protocols.

• Iptacopan Monotherapy Rapidly Improves Hemolysis in PNH: Pha

  2026-06-09

  This phase 2 clinical study demonstrates that oral Iptacopan (LNP023), a selective factor B inhibitor, yields swift and durable reductions in hemolytic markers and transfusion needs in paroxysmal nocturnal hemoglobinuria (PNH) patients. The findings establish Iptacopan monotherapy as a promising alternative pathway-targeted strategy for complement-mediated diseases.

• Sulfo-NHS-SS-Biotin: Precision Reversible Protein Labeling

  2026-06-08

  Sulfo-NHS-SS-Biotin empowers high-specificity, reversible protein and cell surface biotinylation for dynamic interactome and purification workflows. Its unique disulfide-cleavable linker and water solubility enable selective, gentle labeling—ideal for advanced proteomics and affinity applications.

• SN-38 and Camptothecin Inhibit FUBP1–FUSE Binding in Tumors

  2026-06-08

  The reference study reveals that camptothecin and its analog SN-38, beyond inhibiting DNA topoisomerase I, also disrupt the binding of the oncogenic transcriptional regulator FUBP1 to its DNA target FUSE. This dual mechanism provides a new perspective on the therapeutic actions of SN-38 in cancer models, with implications for advanced colon and liver cancer research.

• 7-Ethyl-10-hydroxycamptothecin: Molecular Precision in Colon

  2026-06-07

  Explore how 7-Ethyl-10-hydroxycamptothecin advances colon cancer research through dual topoisomerase I and FUBP1 disruption. This article offers actionable protocol insights and new mechanistic depth beyond current discussions.

• Ratiometric Imaging of Amyloid Beta Fibrils Using Dual-Emiss

  2026-06-06

  This study introduces a dual-emissive tris-heteroleptic ruthenium(II) complex enabling ratiometric imaging detection of amyloid-beta fibrils, offering improved sensitivity and internal referencing over traditional probes. The findings establish a photoluminescent platform for studying Aβ aggregation relevant to Alzheimer’s disease research.

• Oltipraz in Redox Biology: Beyond MASLD—Mechanistic Frontier

  2026-06-05

  Explore how Oltipraz, a potent Nrf2 pathway activator, advances redox biology and chemoprevention. This article goes deeper than standard workflows, offering a mechanistic synthesis and practical insights for researchers.

• PFOS-Induced Ferroptosis and ER Stress in HK-2 Kidney Cells

  2026-06-05

  This study establishes that perfluorooctane sulfonate (PFOS) triggers injury in human renal tubular epithelial (HK-2) cells via both ferroptosis and endoplasmic reticulum (ER) stress pathways. The findings provide mechanistic clarity on PFOS nephrotoxicity and underscore the importance of ER stress modulation in kidney toxicity research.

• Synergistic Meiotic Induction in Mouse SSCs via Retinoic Aci

  2026-06-04

  This study establishes a protocol by which retinoic acid (RA) and nutrient restriction together induce meiotic initiation in cultured mouse spermatogonial stem cells (SSCs)—a longstanding challenge in germline biology. The findings reveal a mechanistic link between metabolic cues and meiotic entry, providing a robust in vitro system for investigating germ cell differentiation and fertility preservation strategies.

16696 records 1/1114 page Next 12345 下5页 Last page